Cochrane · systematic review · CD012922
Pharmacological treatment for central sleep apnoea in adults
Rocha, A, Pinto, ACPereira Nunes, Pachito, DV, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
29
current version
GRADE rated
6
No studies
19
Included studies
NR
No studies 19 · 65.5%Ungraded 4 · 13.8%Very low 6 · 20.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Carbonic anhydrase inhibitors versus inactive control for central sleep apnoea associated with heart failure in adults
Population: adults with central sleep apnoea associated with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
cAHI Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality Carbonic anhydrase inhibitors vs inactive control | OR 0.21 [0.02, 2.48] | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | NR | No studies |
Quality of sleep Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | NR | No studies |
Quality of life Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | NR | No studies |
AHI Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
AHI Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
All‐cause mortality Carbonic anhydrase inhibitors vs inactive control | no estimate extracted | NR | No studies |
Anxiolytics compared to inactive control for central sleep apnoea associated with heart failure in adults
Population: adults with central sleep apnoea associated with heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
cAHI Anxiolytics vs inactive control | no estimate extracted | 1 study · 16 participants | Ungraded |
Cardiovascular mortality Anxiolytics vs inactive control | no estimate extracted | NR | No studies |
Serious adverse events Anxiolytics vs inactive control | no estimate extracted | NR | No studies |
Quality of sleep Anxiolytics vs inactive control | no estimate extracted | NR | No studies |
Quality of life Anxiolytics vs inactive control | no estimate extracted | NR | No studies |
AHI Anxiolytics vs inactive control | no estimate extracted | 1 study · 16 participants | Ungraded |
All‐cause mortality Anxiolytics vs inactive control | no estimate extracted | NR | No studies |
Methylxanthine derivatives versus inactive control for central sleep apnoea associated with heart failure in adults
Population: adults with central sleep apnoea associated with heart failure in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
cAHI Methylxanthine derivatives vs inactive control | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality Methylxanthine derivatives vs inactive control | no estimate extracted | NR | No studies |
Serious adverse events Methylxanthine derivatives vs inactive control | no estimate extracted | NR | No studies |
Quality of sleep Methylxanthine derivatives vs inactive control | no estimate extracted | NR | No studies |
Quality of life Methylxanthine derivatives vs inactive control | no estimate extracted | NR | No studies |
AHI Methylxanthine derivatives vs inactive control | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
All‐cause mortality Methylxanthine derivatives vs inactive control | no estimate extracted | NR | No studies |
Hypnotics compared to inactive control for primary central sleep apnoea in adults
Population: adults with primary central sleep apnoea
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
cAHI Hypnotics vs inactive control | no estimate extracted | 1 study · 5 participants | Ungraded |
Cardiovascular mortality Hypnotics vs inactive control | no estimate extracted | NR | No studies |
Serious adverse events Hypnotics vs inactive control | no estimate extracted | NR | No studies |
Quality of sleep Hypnotics vs inactive control | no estimate extracted | NR | No studies |
Quality of life Hypnotics vs inactive control | no estimate extracted | NR | No studies |
AHI Hypnotics vs inactive control | no estimate extracted | 1 study · 5 participants | Ungraded |
All‐cause mortality Hypnotics vs inactive control | no estimate extracted | NR | No studies |